Related Experiment Video

Updated: Jun 14, 2026

A Treatment Package without Escape Extinction to Address Food Selectivity
04:23

A Treatment Package without Escape Extinction to Address Food Selectivity

Published on: August 21, 2015

11.6K

On-Demand ICS + FABA Combinations in 6-11-Year-Old Children

Elsy M Navarrete-Rodríguez1, Blanca E Del-Rio-Navarro1, Désirée Larenas-Linnemann2

  • 1Secretaría de Salud, Hospital Infantil de México Federico Gómez, Servicio de Alergia e Inmunología Clínica, Ciudad de Mexico 06760, Mexico.

Journal of Clinical Medicine
|December 9, 2023
PubMed

Insights

New asthma treatment strategies, like inhaled corticosteroids (ICS) plus fast-acting beta-agonists (FABA) as a reliever, show benefits in children aged 6-11. This approach combines anti-inflammatory and bronchodilator effects for improved asthma management in younger patients.

Area of Science:

  • Pediatric Pulmonology
  • Pharmacology
  • Asthma Therapeutics

Background:

  • Recent asthma treatment advances include "anti-inflammatory reliever" strategies combining inhaled corticosteroids (ICS) and short-acting beta-agonists.
  • International guidelines have incorporated these strategies, primarily based on evidence in patients over 12 years old.
  • Limited evidence exists for the efficacy and safety of these combined therapies in younger children.

Purpose of the Study:

  • To review and analyze the available information on the use of ICS plus fast-acting beta-agonist (FABA) combination therapy in children aged 6 to 11 years.
  • To assess the potential benefits of this treatment approach in a pediatric population with asthma.
  • To address the scarcity of evidence regarding ICS + FABA use in this specific age group.

Main Methods:

  • Systematic review of published clinical trials investigating ICS + FABA combination therapy in children aged 6-11.
  • Analysis of data from studies utilizing specific ICS/FABA combinations, such as beclomethasone/albuterol and budesonide/formoterol.
  • Evaluation of reported efficacy and safety outcomes from the included trials.

Main Results:

  • Three published trials provide significant insights into ICS + FABA use in children aged 6-11.
  • Studies using beclomethasone + albuterol and budesonide + formoterol suggest therapeutic benefits.
  • The available data indicates positive outcomes associated with this combined treatment approach in the target pediatric population.

Conclusions:

  • The ICS + FABA combination therapy demonstrates significant potential benefits for asthma management in children aged 6 to 11 years.
  • Despite limited trial numbers, existing evidence supports the consideration of this "anti-inflammatory reliever" strategy in this age group.
  • Further research is warranted to expand the evidence base for ICS + FABA use in pediatric asthma patients.

Keywords:
anti-inflammatory rescue therapyasthma treatmentfast-acting beta-agonistschool children

More Related Videos

Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools11:29

Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools

Published on: June 20, 2020

9.1K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.2K

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...